Stock Events

Stock Events

Oculis 

$12.38
21
+$0.31+2.57% Thursday 20:00
+$0.00+0%Thursday 20:04After hours

Statistics

Day High
12.36
Day Low
12.31
52W High
34.48
52W Low
10.52
Volume
5,931
Avg. Volume
-
Mkt Cap
747.6M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.78
-0.65
-0.53
-0.4
Expected EPS
-0.4799675838
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2023
2024
2025
0Revenue
-120.39MNet Income

Analyst Ratings

35.00Average Price Target
The highest estimate is 45.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OCS. It's not an investment recommendation.
NVIDIA
6
NVDA
Microsoft
5
MSFT
Apple
4
AAPL
Meta Platforms
4
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals competes with Oculis in the ophthalmology space, particularly in treatments for eye diseases like age-related macular degeneration.
Novartis
NVS
Mkt Cap293.94B
Novartis is a major player in the development of drugs for eye conditions, directly competing with Oculis in the ophthalmic drug market.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie, through its acquisition of Allergan, has a strong presence in the eye care market, especially in treatments for conditions like dry eye, directly competing with Oculis.
Regenxbio
RGNX
Mkt Cap721.18M
REGENXBIO is involved in gene therapy for ocular diseases, offering innovative treatments that compete with Oculis's drug development efforts.
Bausch Health Companies
BHC
Mkt Cap1.79B
Bausch Health Companies, through its eye health division, competes in the same space as Oculis, particularly in treatments for eye diseases.
Rogers
ROG
Mkt Cap2.45B
Roche, with its ophthalmology division, competes in developing treatments for eye diseases, including macular degeneration and diabetic retinopathy, areas Oculis is also targeting.
GSK
GSK
Mkt Cap105.71B
GlaxoSmithKline has initiatives in developing treatments for eye conditions, potentially competing with Oculis in the broader ophthalmology market.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca, through its acquisition of Alexion Pharmaceuticals, competes in the space of treatments for diseases including those affecting the eye, aligning as a competitor to Oculis.

About

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Show more...
CEO
Dr. Riad Sherif M.B.A., M.D.
Employees
60
Country
Switzerland
ISIN
CH1242303498

Listings

STU
DE
CR5.STU
XNAS
US
OCS
XNAS
US
OCSAW
F
DE
CR5.F

0 Comments

Share your thoughts

FAQ

What is Oculis stock price today?▼
The current price of OCS is $12.38 USD — it has increased by +2.57% in the past 24 hours. Watch Oculis stock price performance more closely on the chart.
What is Oculis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Oculis stocks are traded under the ticker OCS.
Is Oculis stock price growing?▼
OCS stock has risen by +9.46% compared to the previous week, the month change is a -8.7% fall, over the last year Oculis has showed a -31.98% decrease.
What is Oculis market cap?▼
Today Oculis has the market capitalization of 747.6M
What is Oculis revenue for the last year?▼
Oculis revenue for the last year amounts to 0 USD.
What is Oculis net income for the last year?▼
OCS net income for the last year is -120.39M USD.
How many employees does Oculis have?▼
As of August 07, 2026, the company has 60 employees.
In which sector is Oculis located?▼
Oculis operates in the Health & Wellness sector.
When did Oculis complete a stock split?▼
Oculis has not had any recent stock splits.
Where is Oculis headquartered?▼
Oculis is headquartered in Zug, Switzerland.